Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) – Equities research analysts at Wedbush boosted their FY2024 EPS estimates for Apellis Pharmaceuticals in a research report issued to clients and investors on Thursday, January 23rd. Wedbush analyst L. Chico now forecasts that the company will post earnings of ($1.75) per share for the year, up from their prior estimate of ($1.77). The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.70) per share. Wedbush also issued estimates for Apellis Pharmaceuticals’ Q4 2024 earnings at ($0.44) EPS, Q1 2025 earnings at ($0.50) EPS, Q2 2025 earnings at ($0.47) EPS, Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.36) EPS, FY2025 earnings at ($1.75) EPS, FY2026 earnings at ($0.94) EPS, FY2027 earnings at $0.96 EPS, FY2028 earnings at $2.23 EPS and FY2029 earnings at $3.77 EPS.
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) last announced its earnings results on Tuesday, November 5th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.14). The business had revenue of $196.83 million for the quarter, compared to the consensus estimate of $200.00 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The firm’s revenue for the quarter was up 78.3% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.17) earnings per share.
Get Our Latest Stock Analysis on APLS
Apellis Pharmaceuticals Price Performance
Shares of NASDAQ APLS opened at $29.78 on Monday. The business has a fifty day moving average price of $32.15 and a two-hundred day moving average price of $33.06. The stock has a market capitalization of $3.70 billion, a PE ratio of -14.67 and a beta of 0.94. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. Apellis Pharmaceuticals has a fifty-two week low of $24.34 and a fifty-two week high of $71.90.
Hedge Funds Weigh In On Apellis Pharmaceuticals
A number of hedge funds and other institutional investors have recently modified their holdings of APLS. Wolverine Asset Management LLC purchased a new stake in shares of Apellis Pharmaceuticals during the third quarter valued at approximately $27,000. True Wealth Design LLC purchased a new stake in shares of Apellis Pharmaceuticals during the 3rd quarter valued at $27,000. Capital Performance Advisors LLP bought a new stake in shares of Apellis Pharmaceuticals during the 3rd quarter worth $56,000. KBC Group NV boosted its holdings in shares of Apellis Pharmaceuticals by 34.8% in the 3rd quarter. KBC Group NV now owns 2,632 shares of the company’s stock worth $76,000 after buying an additional 679 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in Apellis Pharmaceuticals by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock valued at $130,000 after buying an additional 781 shares during the period. Hedge funds and other institutional investors own 96.29% of the company’s stock.
Insider Transactions at Apellis Pharmaceuticals
In other news, insider Caroline Baumal sold 2,816 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $33.81, for a total value of $95,208.96. Following the completion of the sale, the insider now owns 55,560 shares in the company, valued at $1,878,483.60. This represents a 4.82 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO James George Chopas sold 1,096 shares of the business’s stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $30.43, for a total transaction of $33,351.28. Following the transaction, the chief accounting officer now owns 48,138 shares in the company, valued at approximately $1,464,839.34. This trade represents a 2.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 55,112 shares of company stock valued at $1,655,767 over the last three months. Corporate insiders own 6.80% of the company’s stock.
Apellis Pharmaceuticals Company Profile
Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).
See Also
- Five stocks we like better than Apellis Pharmaceuticals
- What Does a Stock Split Mean?
- Sizing Up a New Opportunity for NVIDIA Investors
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Is DeepSeek Challenging NVIDIA’s AI Dominance?
- There Are Different Types of Stock To Invest In
- The 3 Biggest M&A Stock Opportunities for 2025
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.